89104-47-2

Usage

Uses

Used in Pharmaceutical Industry:
1-O-Octadecyl-2-O-benzyl-rac-glycerol is used as a key intermediate in the synthesis of alkylphospholipids containing modifications of the phosphocholine moiety. These modified alkylphospholipids exhibit antitumor activities and can be employed for the development of novel cancer therapeutics.
Used in Drug Development:
1-O-Octadecyl-2-O-benzyl-rac-glycerol is also utilized in the preparation of platelet-activating factor (PAF) antagonists with modified phosphorylcholine moieties. PAF antagonists are important in the treatment of various inflammatory and cardiovascular conditions, and the modification of their structure can lead to improved efficacy and reduced side effects.

Upstream product

• 10585-86-1 1,2-Di-O-isopropyliden-3-O-octadecyl-sn-glycerin 
• 100-52-7 benzaldehyde 
• 80459-30-9 2-O-Benzyl-1-O-octadecyl-3-O-trityl-sn-glycerin 
• 10567-22-3 (R)-octadecylglycerol 
• 10152-41-7 1-O-octadecyl-2,3-diacetoyl-sn-glycerol 
• 91326-83-9 (4S,5S)-dimethyl 2-phenyl-1,3-dioxolane-4,5-dicarboxylate 
• 3386-32-1 n-octadecyl p-toluenesulfonate 
• 6129-13-1 batyl alcohol 
• 80707-92-2 2-O-Benzyl-3-O-octadecyl-1-O-trityl-sn-glycerin 
• 90904-24-8 (S)-4-Octadecyloxymethyl-2-phenyl-[1,3]dioxolane 
• 16725-43-2 4-(n-octadecyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 112-89-0 1-Bromooctadecane 
• 629-93-6 n-iodooctadecane 
• 14690-00-7 2-O-benzylglycerol 

Downstream Products

• 104478-34-4 2-benzyloxy-3-octadecyloxypropyl 3-trimethylammoniopropyl phosphate 
• 108003-46-9 2-benzyloxy-3-octadecyloxypropyl 4-trimethylammoniobutyl phosphate 
• 111040-51-8 2-benzyloxy-3-octadecyloxypropyl 10-trimethylammoniodecyl phosphate 
• 105415-94-9 (S)-2-benzyloxy-3-octadecyloxypropyl 2-(diethylmethylammonio)ethyl phosphate 
• 105415-95-0 (S)-2-benzyloxy-3-octadecyloxypropyl 2-(N-methylpyrrolidinio)ethyl phosphate 
• 80736-27-2 2-O-Benzyl-3-O-octadecyl-sn-glyceryl-1-phosphorylcholin 
• 105435-57-2 (R)-2-benzyloxy-3-octadecyloxypropyl 2-(diethylmethylammonio)ethyl phosphate 
• 105415-93-8 (R)-2-benzyloxy-3-octadecyloxypropyl 2-(N-methylpyrrolidinio)ethyl phosphate 
• 80483-86-9 2-O-Benzyl-1-O-octadecyl-sn-glycero-3-phosphorylcholin 
• 157837-83-7 C₃₇H₆₂N₃O₁₀P 
• 179391-00-5 1-O-octadecyl-2-O-benzyl-sn-glycero-3-ethylphosphonoformate 

Relevant academic research and scientific papers

PHOSPHOLIPID COMPOUNDS AND USES THEREOF

Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed (Formula (I)).

Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids

Two series of erlotinib-alkylphospholipid hybrids were prepared and evaluated for their antiproliferative activities against a panel of four cell lines representing lung, breast, liver and skin cancers using erlotinib and miltefosine as reference standards. Amide analogs elicited more enhanced cytotoxic activity than analogous esters. Amide derivatives 8d and 8e exhibited promising broad-spectrum antiproliferative activity and higher efficacy than reference erlotinib and miltefosine. Their cellular GI50 values was in the ranges of 24.7–46.9 μM and 26.8–43.1 μM for 8e and 8d respectively. Assay results of the inhibitory activity of the prepared compounds on EGFR kinase reaction and Akt phosphorylation in conjugation with statistical correlation analysis indicated that other mechanisms might contribute to their elicited cytotoxicities. In addition, statistical correlation analysis revealed that mechanisms of elicited cytotoxicities for amide series might be different from ester series. In addition, correlation analysis indicated variations in the mechanisms according to the types of cell line.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue

The clinical use of anticancer lipids is severely limited by their ability to cause lysis of red blood cells prohibiting intravenous injection. Novel delivery systems are therefore required in order to develop anticancer ether lipids (AELs) into clinicall

Chiral PAF agonists: Synthesis, theoretical analysis of their stereoelectronic properties and structure activity relationships

A series of chiral PAF agonists were synthesized. Modifications at the PAF structure were undertaken as far as the C2 substituents and the onium head groups are concerned. In parallel, molecular modelling studies including a MOPAC geometry optimization and the analysis of the electrostatic potential were performed on the newly synthesized and on already known PAF agonists, in order to gain a better insight into the stereoelectronic features required for interaction with the PAF receptor.

Antihypertensive phosphate derivatives

Antihypertensive phosphate derivatives having the following formula are described: STR1 wherein X is a C1 -C24 branched or straight chain alkyl group; R is selected from the group consisting of hydrogen and C1 -C4 alkyl, with the proviso that at least one R group is not hydrogen; T is selected from the group consisting of hydrogen and STR2 wherein R1 is selected from the group consisting of hydrogen, C1 -C4 branched or straight chain alkyl, C1 -C4 branched or straight chain alkoxy and C1 -C4 branched or straight chain alkylamino; Q is a bivalent radical selected from the group consisting of --(CH2)p -- and --(CHR1)p --, wherein p is an integer from 2 to 12 and the moiety --(CHR1)p -- represents an alkylene chain which is substituted by one or more C1 -C10 alkyl groups or phenyl groups; Z is selected from the group consisting of STR3 wherein R2 may be chain alkyl and q is an integer from 4 to 7; in either the racemic or in the optically active form.

Structure-Activity Relationship in PAF-acether. 3. Hydrophobic Contribution to Agonistic Activity

The synthesis of some selected PAF-acether homologues with an alkoxy-chain length from C1 to C20 in position 1 is described.All agonist activities are closely correlated among themselves and with the calculated fatty-chain hydrophobicity.After a discussio

Phosphocholine derivatives having antihypertensive action

Phosphocholine derivatives and compositions are described which are useful as hypotensive agents and in the treatment of hypertension in warm-blooded animals.

Method of use of 1-(alkyl for alkylcarbanoyl)-2-carbamoylglycerol derivatives

Glycerol derivatives, inclusive of salts thereof, of the formula STR1 wherein R1 is alkyl or alkylcarbamoyl containing 10 to 30 carbon atoms, R2 and R3 are independently hydrogen, C1-6 alkyl or, taken together w